Skip to content

Study · Case report or series · n = 1 · 2025

3 results

Semaglutide-Induced Small Bowel Pseudo-Obstruction and Ileitis in a Patient With Type 2 Diabetes: A Case Report.

Javed F, Shaat IAA, Oyibo SO

Cureus20 Jul 2025Cited by 2 (Europe PMC)

PMID40687404 (opens in a new tab)PMCIDPMC12276633 (opens in a new tab)DOI10.7759/cureus.88350 (opens in a new tab)PepBankPUB-40687404
Download PDFPubMedAsk about this study
Jump to 3 results

Summary

Type 2 diabetes mellitus is a major health burden globally, with increasing use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide for glycemic control and cardiovascular risk reduction. While generally well tolerated, GLP-1RAs have been associated with gastrointestinal side effects, including rare reports of bowel obstruction. We describe a case of a 39-year-old male with type 2 diabetes who presented with nausea, vomiting, and abdominal pain five weeks after starting semaglutide. He had four weekly subcutaneous doses of semaglutide 0.25 mg, followed by one dose of 0.5 mg on the fifth week. Examination demonstrated a tender, distended abdomen. Imaging revealed small bowel pseudo-obstruction accompanied by ileitis, with no mechanical cause identified. A diagnosis of bowel pseudo-obstruction was made after exclusion of other causes, including infection, inflammatory bowel disease, and mechanical obstruction. The patient improved with conservative management following drug cessation. Patient education and regular monitoring are crucial, especially for those reporting persistent abdominal symptoms while taking a GLP-1RA for the control of diabetes or weight loss.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In a 39-year-old man with type 2 diabetes, nausea, vomiting and abdominal pain began five weeks after starting semaglutide.

    In plain wordsOne man with type 2 diabetes developed nausea, vomiting and abdominal pain five weeks after starting semaglutide.

    Peptide
    Semaglutide
    Outcome
    Not applicableNausea, vomiting and abdominal pain
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    0.25 mg weekly for four doses, then 0.5 mg · subcutaneous · 5 weeksAs given in this study (human).

    Source sentences

    Summary
    We describe a case of a 39-year-old male with type 2 diabetes who presented with nausea, vomiting, and abdominal pain five weeks after starting semaglutide.
    1 context sentence
    Summary · context
    He had four weekly subcutaneous doses of semaglutide 0.25 mg, followed by one dose of 0.5 mg on the fifth week.
  2. 02HumanCase report or seriesSafety outcome

    In a 39-year-old man with type 2 diabetes, imaging showed small bowel pseudo-obstruction with ileitis and no mechanical cause after starting semaglutide.

    In plain wordsOne man with type 2 diabetes had a bowel blockage-like problem with no physical blockage after starting semaglutide.

    Peptide
    Semaglutide
    Outcome
    Not applicableSmall bowel pseudo-obstruction with ileitis
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    0.25 mg weekly for four doses, then 0.5 mg · subcutaneous · 5 weeksAs given in this study (human).

    Source sentences

    Summary
    Imaging revealed small bowel pseudo-obstruction accompanied by ileitis, with no mechanical cause identified.
    2 context sentences
    Summary · context
    We describe a case of a 39-year-old male with type 2 diabetes who presented with nausea, vomiting, and abdominal pain five weeks after starting semaglutide.
    Summary · context
    He had four weekly subcutaneous doses of semaglutide 0.25 mg, followed by one dose of 0.5 mg on the fifth week.
  3. 03HumanCase report or seriesSafety outcome

    In a 39-year-old man with semaglutide-associated pseudo-obstruction, the patient improved with conservative management after the drug was stopped.

    In plain wordsOne man improved with conservative care after he stopped semaglutide.

    Peptide
    Semaglutide
    Outcome
    Not applicableRecovery after drug cessation
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    0.25 mg weekly for four doses, then 0.5 mg · subcutaneous · 5 weeksAs given in this study (human).

    Source sentences

    Summary
    The patient improved with conservative management following drug cessation.
    1 context sentence
    Summary · context
    We describe a case of a 39-year-old male with type 2 diabetes who presented with nausea, vomiting, and abdominal pain five weeks after starting semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.